Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib.

Ulaner, Gary A

Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research 12 2019 - 7381-7387 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

1557-3265

10.1158/1078-0432.CCR-19-1658 doi


Adult
Aged
Aged, 80 and over
Breast Neoplasms--diagnostic imaging
Breast Neoplasms, Male--diagnostic imaging
Female
Fluorodeoxyglucose F18--metabolism
Humans
Male
Middle Aged
Outcome Assessment, Health Care
Patient Selection
Positron-Emission Tomography--methods
Protein Kinase Inhibitors--therapeutic use
Quinolines--therapeutic use
Radiopharmaceuticals--metabolism
Receptor, ErbB-2--genetics
Response Evaluation Criteria in Solid Tumors
Treatment Outcome